Earnings ·
BioHarvest Sciences Inc. reported second quarter 2026 financial results, posting $8.8 million in revenue, a 3.8%…
BHSTBioharvest Sciences Inc.
BioHarvest Sciences Inc. reported second quarter 2026 financial results, posting $8.8 million in revenue, a 3.8% increase year-over-year, with a net loss of $3.7 million compared to $4.1 million in the prior period. The company secured its first CDMO manufacturing agreement for a rare botanical fragrance ingredient, supporting a planned 20-ton commercial production program over two years. BioHarvest also announced revised full-year guidance, lowering expected CDMO revenue to $4-$5 million and VINIA D2C revenue to $33-$35 million, while narrowing the consolidated EBITDA loss range to $3-$5 million. Additionally, the firm received a $1.4 million grant from the Israel Innovation Authority and advanced its saffron development program with SaffronTech. BioHarvest Sciences Inc. operates in the biotechnology industry, leveraging botanical synthesis technology for contract manufacturing services and consumer wellness products.